Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) - Total Liabilities
Based on the latest financial reports, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) has total liabilities worth €2.91 Billion EUR (≈ $3.41 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited - Total Liabilities Trend (2013–2025)
This chart illustrates how Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's total liabilities have evolved over time, based on quarterly financial data. See Tianjin Zhong Xin Pharmaceutical Group C (2TZ) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Competitors by Total Liabilities
The table below lists competitors of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Logistea AB Series B
ST:LOGI-B
|
Sweden | Skr9.63 Billion |
|
QITIAN Technology Group Co Ltd
SHE:300061
|
China | CN¥684.65 Million |
|
Goldcard High-Tech Co Ltd
SHE:300349
|
China | CN¥2.70 Billion |
|
Bank of Kaohsiung Ltd
TW:2836
|
Taiwan | NT$329.13 Billion |
|
Diagnósticos da América S.A
SA:DASA3
|
Brazil | R$13.26 Billion |
|
Cannae Holdings Inc
NYSE:CNNE
|
USA | $331.60 Million |
|
Collins Foods Ltd
AU:CKF
|
Australia | AU$1.05 Billion |
|
Sunyard System Engineering Co Ltd
SHG:600571
|
China | CN¥619.86 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Tianjin Zhong Xin Pharmaceutical Group C.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2013–2025)
The table below shows the annual total liabilities of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €4.59 Billion ≈ $5.37 Billion |
+57.26% |
| 2024-12-31 | €2.92 Billion ≈ $3.41 Billion |
-18.58% |
| 2023-12-31 | €3.58 Billion ≈ $4.19 Billion |
-0.56% |
| 2022-12-31 | €3.61 Billion ≈ $4.21 Billion |
+41.19% |
| 2021-12-31 | €2.55 Billion ≈ $2.99 Billion |
+9.42% |
| 2020-12-31 | €2.33 Billion ≈ $2.73 Billion |
+0.58% |
| 2019-12-31 | €2.32 Billion ≈ $2.71 Billion |
+13.12% |
| 2018-12-31 | €2.05 Billion ≈ $2.40 Billion |
+2.73% |
| 2017-12-31 | €2.00 Billion ≈ $2.33 Billion |
-3.02% |
| 2016-12-31 | €2.06 Billion ≈ $2.41 Billion |
+4.82% |
| 2015-12-31 | €1.96 Billion ≈ $2.30 Billion |
-21.15% |
| 2014-12-31 | €2.49 Billion ≈ $2.91 Billion |
-7.32% |
| 2013-12-31 | €2.69 Billion ≈ $3.14 Billion |
-- |
About Tianjin Zhong Xin Pharmaceutical Group Corporation Limited
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People's Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and… Read more